Dose‐linearity of the pharmacokinetics of an intravenous [14C]midazolam microdose in children. Issue 10 (30th July 2019)

• Record Type: Journal Article
• Authors: van Groen, Bianca D.; Vaes, Wouter H.; Park, B. Kevin; Krekels, Elke H.J.; van Duijn, Esther; Kõrgvee, Lenne‐Triin; Maruszak, Wioleta; Grynkiewicz, Grzegorz; Garner, R. Colin; Knibbe, Catherijne A.J.; Tibboel, Dick; de Wildt, Saskia N.; Turner, Mark A.
• Is Part Of: British journal of clinical pharmacology. Volume 85:Issue 10(2019)
• Page Start: 2332
• Page End: 2340
• Publication Date: 2019-07-30
• Subjects: cytochrome P450 -- drug metabolism -- paediatrics; Pharmacology -- Periodicals; Drugs -- Periodicals; 615.1
• DOI: 10.1111/bcp.14047
• Languages: English
• ISSNs: 0306-5251

Abstract

Abstract : Aims: Drug disposition in children may vary from adults due to age‐related variation in drug metabolism. Microdose studies present an innovation to study pharmacokinetics (PK) in paediatrics; however, they should be used only when the PK is dose linear. We aimed to assess dose linearity of a [ 14 C]midazolam microdose, by comparing the PK of an intravenous (IV) microtracer (a microdose given simultaneously with a therapeutic midazolam dose), with the PK of a single isolated microdose. Methods: Preterm to 2‐year‐old infants admitted to the intensive care unit received [ 14 C]midazolam IV as a microtracer or microdose, followed by dense blood sampling up to 36 hours. Plasma concentrations of [ 14 C]midazolam and [ 14 C]1‐hydroxy‐midazolam were determined by accelerator mass spectrometry. Noncompartmental PK analysis was performed and a population PK model was developed. Results: Of 15 infants (median gestational age 39.4 [range 23.9–41.4] weeks, postnatal age 11.4 [0.6–49.1] weeks), 6 received a microtracer and 9 a microdose of [ 14 C]midazolam (111 Bq kg −1 ; 37.6 ng kg −1 ). In a 2‐compartment PK model, bodyweight was the most significant covariate for volume of distribution. There was no statistically significant difference in any PK parameter between the microdose and microtracer, nor in the area under curve ratio [ 14 C]1‐OH‐midazolam/[ 14 C]midazolam, showing the PK of midazolam to be linear within the range of the therapeutic and microdoses. Conclusion: Our data support the dose linearity of the PK of an IV [ 14 C]midazolam microdose in children. Hence, a [ 14 C]midazolam microdosing approach may be used as an alternative to a therapeutic dose of midazolam to study developmental changes in hepatic CYP3A activity in young children.